A comparative study of Olanzapine and Haloperidol in treating Delirium in ICU settings

Efficacy of Olanzapine vs Haloperidol in treating Delirium in intensive care settings â?? a comparative study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/051110

Enrollment

320

Registered

2023-03-28

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F01-F09- Mental disorders due to known physiological conditions

Interventions

Intervention1: Olanzapine: Prescribing Olanzapine (up to 5 mg per day) for 3 days (72 hours) in patients diagnosed with Delirium in ICU Intervention2: Haloperidol: Prescribing Haloperidol (up to 2.5 m

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients in ICU (medical and surgical) diagnosed with Delirium 2. Patients of both genders, above 18 years of age 3. Patients whose primary caregiver (legally authorized representative) has given consent for the patientâ??s inclusion in the study 4. Patients who stayed in the ICU for a minimum of 72 hours

Exclusion criteria

Exclusion criteria: 1. Patients whose caregivers did not give consent 2. Patients of Delirium purely due to complicated Alcohol Withdrawal

Design outcomes

Primary

Measure	Time frame
Severity of DeliriumTimepoint: Zero hour, 72 hours	—

Secondary

Measure	Time frame
Extrapyramidal side effectsTimepoint: 72 hours	—

Countries

India

Contacts

Public ContactBhakti Murkey

Pacific Medical College and Hospital

doctor.bhaktii@gmail.com9799206939

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026